Annexe B: Changes to the selective neonatal Hepatitis B immunisation pathway for babies born to Hepatitis B infected mothers
Published 30 April 2025
© Crown copyright 2025
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/changes-to-the-routine-childhood-schedule-letter/annexe-b-changes-to-the-selective-neonatal-hepatitis-b-immunisation-pathway-for-babies-born-to-hepatitis-b-infected-mothers
| Age | Vaccine | Change |
|---|---|---|
| At birth | Monovalent hepatitis B (Engerix B/ HBvaxPRO) | None |
| 4 weeks | Monovalent hepatitis B (Engerix B/ HBvaxPRO) | None |
| 1 year | Remove monovalent Hepatitis B (Engerix B/HBvaxPRO) vaccine dose (note 1) Blood test (usually performed as a dried blood test) for HepB surface antigen to be completed between one year and 18 months of age |
Note 1: This final HepB dose will be provided by the additional routine Hexavalent dose (4th dose of DTaP/IPV/Hib/HepB) offered at 18 months.